A2A 03
Alternative Names: A2A-03; A2A-O-03; A2A_O-03; KRAS protein degrader - A2A PharmaceuticalsLatest Information Update: 26 Nov 2021
Price :
$50 *
At a glance
- Originator A2A Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 26 Nov 2021 A2A Pharmaceuticals announces intention to submit IND to US FDA for Solid tumours in the first half of 2023 (A2A Pharmaceuticals pipeline, November 2021)
- 19 Jan 2021 Early research in Solid tumours in USA (unspecified route) (A2A Pharmaceuticals pipeline, January 2021)
- 19 Jan 2021 A2A Pharmaceuticals plans clinical development in Solid tumours (A2A Pharmaceuticals pipeline, January 2021)